Triple Negative Breast Carcinoma (DBCOND0129280)

Identifiers

Synonyms

Triple-Negative Breast Carcinoma

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04959474	Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer	No drug interventions	supportive_care	Not Available	recruiting
NCT03232593	A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)	Atezolizumab	Not Available	Not Available	completed
NCT02876107	Carboplatin and Paclitaxel with or Without Panitumumab in Treating Patients with Invasive Triple Negative Breast Cancer	Carboplatin Paclitaxel Panitumumab	treatment	2	active_not_recruiting
NCT02954874	Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer	Pembrolizumab	treatment	3	active_not_recruiting
NCT03207529	Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer	Alpelisib Enzalutamide	treatment	1	completed
NCT06635980	Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer	No drug interventions	treatment	2	not_yet_recruiting
NCT03872388	Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy	Atorvastatin Capecitabine	treatment	2	terminated
NCT06422455	Access to Genetic Testing in Underserved Patients With Cancer	No drug interventions	health_services_research	Not Available	not_yet_recruiting
NCT05677802	Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer	No drug interventions	health_services_research	Not Available	recruiting
NCT02945579	Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy	No drug interventions	treatment	Not Available	recruiting
NCT01238133	Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer	Carboplatin Paclitaxel RG-4733	treatment	1	terminated
NCT00576654	Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery	Camptothecin Irinotecan Veliparib	treatment	1	active_not_recruiting
NCT02744053	DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer	Technetium Tc-99m sestamibi Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate	diagnostic	0	active_not_recruiting
NCT02648477	Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer	Anastrozole Doxorubicin Exemestane Letrozole Pembrolizumab	treatment	2	completed
NCT00861705	Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery	Bevacizumab Carboplatin Cyclophosphamide Doxorubicin Paclitaxel	treatment	2	active_not_recruiting
NCT04139993	RBX7455 Before Surgery for the Treatment of Operable Breast Cancer	No drug interventions	treatment	1	terminated
NCT03971409	Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer	Avelumab Binimetinib Doxorubicin Ivuxolimab Sacituzumab govitecan Utomilumab	treatment	2	recruiting
NCT02411656	Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy	Pembrolizumab	treatment	2	active_not_recruiting
NCT02672475	Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer	Galunisertib Paclitaxel	treatment	1	completed
NCT02208375	mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian	Capivasertib Olaparib Vistusertib	treatment	1 / 2	active_not_recruiting
NCT02593175	Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC	Carboplatin Paclitaxel Panitumumab	treatment	2	active_not_recruiting
NCT00892736	Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy	Veliparib	treatment	1	completed
NCT02498613	A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	Cediranib Olaparib	treatment	2	active_not_recruiting
NCT01276496	Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery	Cilengitide Paclitaxel	treatment	1	completed
NCT05455658	STEMVAC in Patients With Early Stage Triple Negative Breast Cancer	Sargramostim	prevention	2	recruiting
NCT03326258	Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery	Glembatumumab vedotin Ipilimumab Nivolumab	treatment	1 / 2	withdrawn
NCT02432963	Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy	Modified vaccinia ankara Pembrolizumab	treatment	1	active_not_recruiting
NCT01319539	MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer	No drug interventions	treatment	2	terminated
NCT02996825	Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	Gemcitabine Mirvetuximab Mirvetuximab soravtansine	treatment	1	completed
NCT01145430	Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer	Doxorubicin Tetracycline Veliparib	treatment	1	completed
NCT03012230	Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer	Pembrolizumab Ruxolitinib	treatment	1	completed
NCT02456857	Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative	Bevacizumab Doxorubicin Everolimus Tetracycline	treatment	2	completed
NCT01750073	Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer	Cyclophosphamide Doxorubicin Paclitaxel Trastuzumab	treatment	2	active_not_recruiting
NCT02474173	Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer	Onalespib Paclitaxel	treatment	1	terminated
NCT02599194	18F-FSPG PET/CT for Cancer Patients on Therapy	Florilglutamic acid F-18 Fludeoxyglucose (18F)	diagnostic	2	completed
NCT02445391	Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy	Capecitabine Carboplatin Cisplatin	treatment	3	active_not_recruiting
NCT01846091	Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer	Measles virus vaccine live attenuated Sodium iodide	treatment	1	completed
NCT02883062	Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer	Atezolizumab Carboplatin Paclitaxel	treatment	2	completed
NCT02530489	Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer	Albumin human Atezolizumab Paclitaxel	treatment	2	active_not_recruiting
NCT04216472	Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations	Albumin human Alpelisib Paclitaxel	treatment	2	active_not_recruiting
NCT02957968	Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca	Carboplatin Cyclophosphamide Decitabine Doxorubicin Paclitaxel Pembrolizumab	treatment	2	active_not_recruiting
NCT02993068	Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)	No drug interventions	diagnostic	Not Available	recruiting
NCT02120469	Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer	Eribulin Everolimus	treatment	1	completed
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Cyclophosphamide Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT02419495	Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	Calcium Camptothecin Capecitabine Carboplatin Cyclophosphamide Daunorubicin Doxorubicin Eribulin Escitalopram Fluorouracil Ipilimumab Irinotecan Leucovorin Levoleucovorin Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	treatment	1	active_not_recruiting
NCT03291938	IACS-010759 in Advanced Cancers	No drug interventions	treatment	1	completed
NCT02276443	Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative	No drug interventions	treatment	Not Available	recruiting
NCT03154190	Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer	No drug interventions	health_services_research	Not Available	unknown_status
NCT01071564	RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery	RG-4733 Vismodegib	treatment	1	terminated
NCT05071677	Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT03106077	Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer	Mirvetuximab Mirvetuximab soravtansine	treatment	2	completed
NCT04835597	Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy	No drug interventions	Not Available	Not Available	terminated
NCT05111561	Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	Binimetinib	treatment	1	suspended
NCT04185311	Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted	Ipilimumab Nivolumab Talimogene laherparepvec	treatment	1	terminated
NCT06582615	Food for Thought - a Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer	No drug interventions	supportive_care	Not Available	recruiting
NCT03012100	Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer	Benzalkonium Cyclophosphamide Folic acid Sargramostim	treatment	2	active_not_recruiting
NCT03715959	Nipple Aspirate Fluid in Detecting Breast Cancer	No drug interventions	diagnostic	Not Available	active_not_recruiting
NCT01349959	Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer	Azacitidine Entinostat	treatment	2	active_not_recruiting
NCT04491942	Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer	Chloride ion Cisplatin Elimusertib Gemcitabine Platinum	treatment	1	active_not_recruiting
NCT01624441	Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer	Dinaciclib Epirubicin	treatment	1	completed
NCT03213041	Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer	Carboplatin Pembrolizumab	treatment	2	recruiting
NCT01964924	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	Trametinib Uprosertib	treatment	2	completed
NCT05177796	Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer	Carboplatin Cyclophosphamide Daunorubicin Doxorubicin Paclitaxel Panitumumab Pembrolizumab	treatment	2	withdrawn
NCT02567396	Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction	Talazoparib	treatment	1	withdrawn
NCT01575522	Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer	Tivantinib	treatment	2	completed
NCT03544125	Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer	Durvalumab Olaparib	treatment	1	completed
NCT03044730	Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery	Capecitabine Pembrolizumab	treatment	2	unknown_status
NCT02627430	Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer	Onalespib Talazoparib	treatment	1	withdrawn
NCT01116648	Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	Cediranib Olaparib	treatment	1 / 2	active_not_recruiting
NCT03218826	PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	AZD-8186 Docetaxel	treatment	1	active_not_recruiting
NCT01251874	Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer	Carboplatin Veliparib	treatment	1	completed
NCT05086731	Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer	No drug interventions	health_services_research	Not Available	active_not_recruiting
NCT02689427	Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer	Enzalutamide Paclitaxel	treatment	2	completed
NCT04081389	Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer	Benzalkonium Celecoxib Cyclophosphamide Daunorubicin Doxorubicin Interferon alfa Interferon alfa-2b Paclitaxel Rintatolimod	treatment	1	completed
NCT03199040	Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy	Durvalumab	treatment	1	terminated
NCT02488967	Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer	Carboplatin Cyclophosphamide Doxorubicin Paclitaxel	treatment	3	active_not_recruiting
NCT02457910	Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer	Enzalutamide Taselisib	treatment	1 / 2	terminated
NCT01957514	Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy	No drug interventions	Not Available	Not Available	terminated
NCT04052555	Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer	Berzosertib	treatment	1	active_not_recruiting
NCT01281150	Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors	Carboplatin Paclitaxel Veliparib	treatment	1	completed
NCT03979508	Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer	Abemaciclib	treatment	2	recruiting